Health
STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes – medwireNews
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors…
medwireNews: The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Improvements in glycemic control were relatively small, with glycated hemoglobin (HbA1c) levels falling by an average of 1.6% (17.5 mmol/mol) among people randomly assigned to receive weekly semaglutide 2.4 mg for 68 weeks and 1.5% (15.9 mmol/mol) among those given…
-
Noosa News24 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General17 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News24 hours agoFrank Moneger identified as man accused of hit-and-run death of 17-year-old girl in Margate, Queensland